Video: Major chemical to be removed from kids' drugs
The Food and Drug Administration (FDA) announced last week that the agency will be taking action to remove prescription drug products with ingestible fluoride for children from the market.
In a Department of Health and Human Services press release last Tuesday, President Donald Trump's administration confirmed that the FDA would be taking action after studies have shown that ingestible fluoride can 'alter the gut microbiome, which is of magnified concern given the early development of the gut microbiome in childhood.' The press release also noted that studies have indicated that there may be a connection between fluoride and weight gain, thyroid disorders, and a decreased IQ.
The FDA explained that unlike fluoride's inclusion in toothpaste and mouth rinses, child drug products with ingestible fluoride, which have not been approved by the agency, are 'swallowed and ingested by infants and toddlers.'
In a video statement highlighting the FDA's action against ingestible fluoride in children's prescription drugs, Makary warned that drugs containing fluoride are currently 'prescribed to infants as young as six months of age.'
Today, the FDA is taking action to remove concentrated ingestible fluoride prescription drug products for children from the market. A growing body of research is demonstrating how ingested fluoride can alter the gut microbiome. This is especially concerning with young children… pic.twitter.com/pKTtkGyV3J — Dr. Martin Makary (@DrMakaryFDA) May 13, 2025
'The best way to prevent cavities in children is by avoiding excessive sugar intake and good dental hygiene, not by altering a child's microbiome,' FDA Commissioner Marty Makary said. 'For the same reason that fluoride may kill bacteria on teeth, it may also kill intestinal bacteria important for a child's health.'
READ MORE: Video: Trump order against 'Big Pharma' aims to reduce drug prices
'I am instructing our Center for Drug Evaluation and Research to evaluate the evidence regarding the risks of systemic fluoride exposure from FDA-regulated pediatric ingestible fluoride prescription drug products to better inform parents and the medical community on this emerging area,' Makary added. 'When it comes to children, we should err on the side of safety.'
In last week's press release, the FDA announced that it would complete a safety review and public comment period by October 31 and that the agency would take 'appropriate action' regarding the removal of ingestible fluoride prescription drug products for children from the market.
In a statement on X, formerly Twitter, Health and Human Services Secretary Robert F. Kennedy Jr. expressed his support for the FDA's action against ingestible fluoride in children's drugs. He explained that a recent review of 74 'high-quality studies' discovered a 'clear association between fluoride exposure and reduced IQ in children.'
'This isn't fringe science—this is mainstream, peer-reviewed data,' Kennedy tweeted. 'Yes, when it comes to children, we should always err on the side of safety.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
RESTEM to Present Phase 2/3 IIMPACT Trial Design in Idiopathic Inflammatory Myopathy at EULAR 2025 Congress
MIAMI, June 06, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that it will present the rationale and study design of its Phase 2/3 IIMPACT (Idiopathic Inflammatory Myopathy Phase 2/3 Adaptive Clinical Trial) trial of Restem-L, the Company's umbilical-lining modified progenitor cells (UMPC) program for the treatment of Polymyositis and Dermatomyositis (PM/DM), a rare autoimmune disease, now defined by the FDA as Idiopathic Inflammatory Myopathy (IIM). The oral presentation will be delivered at the European Alliance of Associations for Rheumatology's (EULAR) 2025 Congress, to take place June 11-14 in Barcelona, Spain. Details of the oral presentation are as follows: Abstract Title: Rationale and Study Design for a Phase 2/3, Double-blinded, Randomized, Dose-repeating, Cross-over Study to Assess Safety and Efficacy of Allogeneic Umbilical Cord Lining Stem Cells on Disease Severity and Steroid Tapering in Participants with Idiopathic Inflammatory Myopathy Abstract Number: OP0318 Session Title: Clinical Abstract Sessions: Novelties and innovative therapeutic strategies in inflammatory myopathies Session Date and Time: Friday, June 13, 2025, 10:30 AM CEST About Idiopathic Inflammatory Myopathy (IIM) Idiopathic inflammatory myopathies (IIM) are a group of conditions characterized by inflammation of muscles (myositis) and other body systems. Polymyositis and dermatomyositis are subtypes of IIM. Polymyositis causes inflammation and weakness of the skeletal muscles responsible for movement. Dermatomyositis is a form of polymyositis that is associated with skin rash, in addition to muscle inflammation. Both disorders can significantly compromise the quality of life and are very challenging to treat. Currently, the only treatment for these disorders is immunosuppressive drugs, which can be associated with significant toxicity and other side effects. About RESTEM RESTEM is a leading clinical-stage biotechnology company focused on developing off-the-shelf, next-generation cell therapies designed to modulate the immune system. Leveraging our proprietary products, robust clinical development expertise, and cutting-edge-manufacturing capabilities, we are advancing two potentially groundbreaking programs, Restem-L, our umbilical-lining modified progenitor cells (UMPC) program for autoimmune diseases; and our activated natural killer cell (aNK) therapeutics targeting senescence and age-associated disorders. Our therapies are uniquely positioned to redefine the standard of care for patients with limited options, by suggesting an immune system remodeling—rather than mere symptom suppression—offering a potential path to true disease resolution. RESTEM is headquartered in Miami, Florida. For more information, please visit and follow us on X and LinkedIn. Investor Contact Daniel Ferry LifeSci Advisors +1.617.430.7576 daniel@ Media Contact Nelson CabautanRestem Group, Inc. +1.800.490.0924 ncabatuan@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CBS News
an hour ago
- CBS News
FDA food inspector vacancies near 20% after Trump hiring freeze
Nearly 1 in 5 positions across the Food and Drug Administration's human food inspection divisions are now vacant, multiple agency officials tell CBS News, in the wake of departures encouraged by the Trump administration's cost-cutting efforts and a government-wide hiring freeze that had stalled efforts to replenish their ranks. While the FDA has long struggled with hiring and retaining qualified investigators to inspect food producers and distributors, multiple federal health officials — who spoke on the condition of anonymity and were not authorized to speak to the press — say that the staffing gap has worsened due to early retirements and resignations. "The FDA remains fully capable of fulfilling its public health mission to protect the safety of the American people. Under Commissioner Makary's leadership, the agency continues to meet its inspection obligations, ensuring that all facilities are reviewed within mandated timeframes," Emily Hilliard, a spokesperson for the Department of Health and Human Services, told CBS News. FDA Commissioner Dr. Marty Makary has claimed in interviews that no inspectors were laid off at the agency as a result of the sweeping restructuring ordered by Health and Human Services Secretary Robert F. Kennedy Jr. that began in April, but has not acknowledged the retirements and resignations. And despite Makary's statements, multiple FDA officials said they are worried about worsening attrition in the agency's ranks of investigators. "They're not going to admit our mission is at risk and we're missing timeframes, even though I've heard that's happening," a current FDA official told CBS News in a message. A separate current FDA official and one former official said that close to 20% of investigational positions are vacant across the agency's human foods inspectorate. "Since 2017, our ability to fulfill its public health mission is increasingly constrained by reduced inspectional capacity. We continue to face significant obstacles in recruiting and retaining qualified investigators, particularly in the foods program, where nearly 90 investigative positions remain vacant," the agency said last month in response to a draft of a report by the HHS inspector general. The inspector general had concluded that the FDA would need to increase inspections by more than 3,000 each year, in order to meet its goals. Under requirements laid out by Congress, the FDA is required to inspect food facilities at specific intervals, benchmarks that government watchdogs have long faulted the agency for falling short of. "For FDA to meet the inspection timeframes moving forward, it would need to inspect approximately 7,000 high-risk facilities each year. However, FDA inspected only about 58 percent of that amount," the inspector general's June 2025 report said. Around 40% of investigator positions are vacant for the group of investigators tasked with inspecting "critical foods" like infant formula plants, a current official said. "Critical foods has had difficulty with staffing because every inspection is high profile and the team is traveling more often than not. It isn't sustainable for everyone," a former FDA official said. The job of an FDA investigator has gotten harder in recent months, as the Trump administration imposed additional hurdles to make small purchases necessary for their work, ranging from buying everyday supplies to shipping samples, officials said. "The reality is that the extra steps in budget approval processes have caused inspections to be delayed, and investigators have had to take on administrative tasks that eat into their time being productive. Everything was taking longer," the former FDA official said. Many administrative staff and laboratory scientists supporting the FDA's food inspectors were also eliminated through layoffs, resulting in backlogs of testing and reimbursements. Some have since been reinstated by the agency. One current and one former FDA official said the agency also had many investigators that were in the process of being hired months ago, before attempts to fill the slots were blocked by an order signed by President Trump that now extends through July 15. Multiple officials said Friday morning they were hopeful that the Trump administration might grant an exemption to the hiring freeze after weeks of lobbying by officials within the agency. On Friday afternoon, after HHS responded to a CBS News request for comment about this story, the FDA published its first new hiring announcement for food investigators in months, among a handful of new job postings. "This position is being filled under a stream-lined hiring authority," the job posting reads.
Time Business News
an hour ago
- Time Business News
Choosing the Right Addiction Treatment Can Change Your Life Forever
Addiction is not a monolith. It is an intricate interweaving of biological, psychological, and social threads that ensnare the individual in a cycle of compulsive behavior. While often perceived as a failure of willpower, substance dependency is in fact a chronic, relapsing condition that rewires the brain's reward circuitry. The compulsions associated with addiction arise from alterations in dopamine pathways, deeply entangling emotion and cognition. Environmental triggers, trauma, and co-occurring disorders like anxiety or depression further complicate the picture. Effective treatment, therefore, must reach far beyond detox to address this vast and tangled web. Overcoming dependency on alcohol requires a compassionate and structured approach. Individuals battling with excessive consumption often face physical, emotional, and psychological challenges that hinder recovery. Midway through their journey, Alcohol Addiction Treatment becomes a cornerstone in building resilience and reclaiming control. This process may involve counseling, medical support, lifestyle changes, and strong social networks. Every small victory reinforces progress and opens the door to lasting change. While setbacks may occur, persistence and tailored care lead to gradual healing. Embracing support systems and professional guidance empowers individuals to move forward, fostering a renewed sense of purpose and well-being. There comes a moment—subtle for some, harrowing for others—when the veil lifts and reality sets in. Perhaps it's a missed day at work, a broken relationship, or an inexplicable moment of self-awareness. Regardless, the acknowledgment of needing help is a pivotal step. Common indicators include increased tolerance, withdrawal symptoms, secrecy, and a gradual erosion of responsibilities. Despite this clarity, many attempt to go it alone. Self-detox, often glorified in media, is fraught with danger—from physical risks like seizures to psychological implosions. Professional intervention is not a luxury; it is a necessity. Treatment exists on a spectrum—flexible and diverse to meet varying degrees of severity and lifestyle constraints. Inpatient treatment offers an immersive, structured environment. It removes the individual from triggers and allows for constant medical and psychological support. Ideal for those with long-standing or high-risk dependencies, it fosters concentrated healing. Outpatient programs, by contrast, provide autonomy. Participants live at home and attend scheduled therapy sessions. This modality suits individuals with milder addictions or strong support systems. Beyond these models, holistic therapies integrate mind, body, and spirit. Practices like yoga, acupuncture, and equine therapy offer catharsis and reconnection. Meanwhile, Medication-Assisted Treatment (MAT)—using FDA-approved drugs like buprenorphine or naltrexone—can stabilize cravings and normalize brain chemistry. A multifaceted problem demands a multifaceted solution. Addiction wears a different face on every person. A teenager experimenting with pills has distinct needs from a middle-aged alcoholic or a veteran struggling with PTSD. A successful recovery hinges on personalized care—treatment plans built around the individual's history, culture, gender identity, and even neurodiversity. Cultural relevance, for instance, can drastically improve engagement and trust. Psychological profiles help determine therapy methods, while lifestyle choices dictate practicalities such as inpatient vs. outpatient feasibility. The human soul doesn't thrive in cookie-cutter molds. Healing begins with recognition of uniqueness. Not all facilities are created equal. When seeking treatment, the decision of where to go is as crucial as how to go. A credible treatment center should carry appropriate accreditations such as those from the Joint Commission or CARF. These ensure adherence to clinical and ethical standards. Look for staff qualifications—licensed therapists, board-certified physicians, and a robust multidisciplinary team. Transparency in success rates, availability of aftercare, and integration of evidence-based practices also signal quality. Beware of glossy marketing that obscures questionable practices. Instead, favor centers that offer real stories, measurable outcomes, and patient-centered care. Recovery doesn't end with a graduation certificate or a final therapy session. It is an ongoing, ever-evolving odyssey. Reintegration into daily life introduces new challenges—old friends, familiar stressors, or unexpected triggers. Establishing a support system is vital. This could include 12-step groups, sober companions, family therapy, or mentorship. Relapse prevention is another cornerstone. Tools like mindfulness, cognitive behavioral strategies, and contingency planning help navigate turbulent moments. More importantly, anchoring oneself in purpose—volunteering, creative pursuits, career goals—provides a lodestar for sustained transformation. Community, too, plays an irreplaceable role. Connection mitigates isolation, instills accountability, and restores a sense of belonging. Choosing the right addiction treatment isn't just a medical decision—it's a lifeline. It can dismantle years of pain, rewire the psyche, and illuminate a path forward. With the right approach, what once seemed insurmountable becomes manageable. Transformation begins with that first courageous step. In the right environment, with the right support, addiction is not the end of a story—it is the beginning of a new, empowered chapter. TIME BUSINESS NEWS
